Text and Data Mining valid from 2019-02-22
Received: 6 September 2018
Accepted: 10 February 2019
First Online: 22 February 2019
Ethics approval and consent to participate
: All patients provided informed written consent and all study protocols were approved by ethics committees at each BIG 1–98 study center and by relevant health authorities.
: Not applicable.
: MMR has received research funding for IBCSG clinical trials from Novartis, Pfizer, Ipsen, Merck, Ferring, and Pierre Fabre and research funding from Novartis, Veridex, OncoGenex, Bayer, and Bristol-Myers Squibb, and serves in a consulting or advisory role for Ipsen and Bristol-Myers Squibb. MC receives an honorarium from Novartis and is a consultant for Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, Celldex, and AstraZeneca. MB receives sponsored research support from and has been a consultant to Novartis. MB has served on the scientific advisory board of Gtx, Inc. and currently serves on the scientific advisory board of Kronos Bio.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.